Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of XNW5004 tablets in relapsed or refractory peripheral T-cell lymphoma
ChiCTR2400092826Phase 2Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of igermetostat in peripheral T-cell lymphoma (PTCL), sponsored by Hunan Cancer Hospital. Primary endpoint: objective response rate. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
igermetostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ChiCTR2400092826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092826.